About J3M-MC-JZQH
This app has been exclusively created for participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC.
It contains Televisit functionality and allows participants to complete questionnaires.
The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)
It contains Televisit functionality and allows participants to complete questionnaires.
The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)
J3M-MC-JZQH Screenshots
Tap to Rate:
